In 2018, Japanese multinational conglomerate Fujifilm up and decided it wanted to become a major player in supplying cell and gene therapy manufacturing, so it purchased two key companies—one in the U.S. and in the other in Japan—to jump-start its goal.
Four years later, the spending spree continues: Fujifilm has gobbled up Shenandoah Biotechnology for an undisclosed sum, again to increase its cell and gene therapy capabilities.
The Warminster, Pennsylvania-based Shenandoah boosts Fujifilm’s ability to produce recombinant proteins—especially growth factors and cytokines—used in manufacturing cell and gene therapies.
Shenandoah also comes with an upgraded cGMP facility with bio-command software, a new Tuttnauer autoclave sterilizer, a 16×16 ColdBox, and new air handling and RODI water systems, according to its website.
“Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific, said in a release.
Fujifilm said it welcomed “all members” of the Shenandoah team. The privately held company was established in 2006.
In 2018, Fujifilm dove headfirst into the cell and gene therapy supply business with its simultaneous acquisition of Irvine Scientific Sales of California and IS Japan for $800 million.
Then, in September of last year, Fujifilm completed construction of a 250,000-square-foot facility in Tilburg, Netherlands. The site produces dry powder media and liquid media along with other raw materials used in producing cell and gene therapies. It also gave Fujifilm Irvine Scientific a hub from which to serve its customers in Europe.
By Kevin Dunleavy
Source: fiercepharma.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
